N/A N=34 Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training
Sarcopenia · Osteoporosis · Aging
Primary: Change in Total Body Fat-free Mass — 1.5; 2.3; 0.7 kg — p=0.38
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)
Rhinitis, Allergic, Perennial · Asthma
Primary: Difference in German Cockroach-Specific Serum IgE Over Time — 2.16; 1.12 Ratio — p=<0.0001
N/A N=65 Study of the Cell Response in the Tear Film After Overnight Contact Lens Wear
White Blood Cells
Primary: Leukocyte Population — 583187; 420345; 738140 Leukocytes
N/A N=62 CoolCap Followup Study-Coordination of Participating Centers
Neonatal Encephalopathy
Primary: WeeFIM Score — 78; 80 percentage of participants
Phase 2 N=33 A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
Human Immunodeficiency Virus Type 1
Primary: Mean Changes From Baseline in Plasma log10 Human Immunodeficiency Virus Type 1 Ribonucleic Acid (HIV-1 RNA) — 4.72; 4.36; 4.78; 4.71 log10 copies/mL
Phase 3 N=567 A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 6.8 Years — 89.1 percentage of participants
N/A N=500 Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience
Chronic Kidney Failure · Secondary Hyperparathyroidism
Primary: Intact Parathormone (iPTH) Changes During the Study Time-Points for Overall Study Population — 232.1; 200.1; 166.6; 157.3 pg/mL
Phase 3 N=162 STRIPS: Shoulder Taping Reduces Injury and Pain in Stroke
Stroke · Shoulder Injury
Primary: Pain: Visual Analog Scale — -2.3; 1.4; -9.2; 2.6 mm — p=0.03
Phase 2 N=36 Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
Colon Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 55 percentage of patients
Phase 2 N=30 Varenicline for Smoking Cessation in Heavy Drinking Smokers
Nicotine Dependence · Smoking · Heavy Drinking
Primary: Number of Participants Reporting Continuous Smoking Abstinence in the Extended Varenicline Pretreatment Versus Short-term Varenicline Pretreatment Conditions. — 4; 2…
Phase 2 N=16 An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures
Epilepsy · Partial Onset Seizures
Primary: Incidence of Treatment Emergent Adverse Events During the Entire Study Period (up to 32 Days) — 5 participants
N/A N=110 A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse…
Phase 3 N=503 An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).
HIV-1
Primary: The Number of Participants Experiencing Adverse Events — 46; 42; 88; 160 Participants
Phase 3 N=512 Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS) — 4.28; 3.91 months — p=0.1933
N/A N=20 Evaluation of Acclimate Feature for Positive Airway Pressure (PAP) Therapy
Obstructive Sleep Apnea
Primary: Hours Used — 146.9; 141.9 Total Hours Used